Heart Failure and Central Sleep Apnea

The Facts

The remedē® System is designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central Sleep Apnea.

  • Central Sleep Apnea (CSA) is a type of sleep disordered breathing, a condition that disturbs the normal breathing pattern during sleep and has an adverse effect on overall cardiovascular health.
  • Heart failure patients have a 1 in 3 chance of having CSA.
  • Symptoms of CSA are often silent such as fatigue, poor energy, and nocturia and resemble those of the underlying heart failure.
  • CSA worsens heart failure progression, increases risk of hospitalization, cardiac arrhythmias, and death.
  • Even in patients without heart failure at diagnosis, CSA increases morbidity and mortality.
  • Cheyne-Stokes Respiration is a form of CSA, often identified at night, but can occur when awake.

References

  • Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007;9:251-7.
  • Schulz R, Blau A, Borgel J, et al. Sleep apnea in heart failure. Eur Respir J 2007;29:1201-5.
  • Bitter T, Langer C, Vogt J, et al.. Sleep-disordered breathing in patients with atrial fibrillation and normal systolic left ventricular function. Dtsch Arztebl Int 2009;106:164-70.
  • Javaheri S, Shukla R, Zeigler H, Wexler L. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. Table reprinted by permission of Elsevier. J Am Coll Cardiol 2007;49:2028-34.
  • Khayat R, Pederzoli A, Abraham W. Central Sleep Apnea in Heart Failure. US Cardiology 2009;6:72 – 78.
  • Oldenburg O, Schmidt A, Lamp B, et al. Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration. Eur J Heart Fail 2008;10:581-6.
  • Zhang XL, Yin KS, Li XL, et al. Efficacy of adaptive servoventilation in patients with congestive heart failure and Cheyne-Stokes respiration. Chin Med J (Engl) 2006;119:622-7.
  • Kalorama. Congestive Heart Failure: Worldwide Drug and Medical Device Markets. 2002:334.
  • AHA. Heart Disease and Stroke Statistics 2010 Update. American Heart Association 2010.
  • Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002;87:235-41.
  • Hobbs FD, Kenkre JE, Roalfe AK, et al.. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-76.
  • Khayat RN, Jarjoura D, Patt B, et al. In-hospital testing for sleep-disordered breathing in hospitalized patients with decompensated heart failure: report of prevalence and patient characteristics. J Card Fail 2009;15:739-46.
  • Levy P, Pepin JL, Tamisier R, et al. Prevalence and Impact of Central Sleep Apnea in Heart Failure. Sleep Medicine Clinics 2007;2:615 – 621.
  • Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 2003;168:1109-14.
  • clinicaltrials.gov/ct2/show/NCT00733343
  • Jilek C, Krenn M, Sebah D, et al. Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study. European Heart Journal 2011;13:68-75.
  • Javaheri S, Dempsey JA. Central sleep apnea. Compr Physiol 2013;3:141–163.
  • Khayat R, Abraham WT, and Patt B.  Central Sleep Apnea is a Predictor of Cardiac Readmission in Hospitalized Patients With Systolic Heart Failure.  J Card Fail  2012; 18:534-540.

1 in 3 people with heart failure have Central Sleep Apnea and stop breathing during the night. Talk to your doctor about the remedē® System clinical study to see if you qualify.
Send us an email at info@respicardia.com or read about our clinical study at www.clinicaltrials.gov.

CONTACT US

Respicardia®, Inc.
12400 Whitewater Dr., Suite 150
Minnetonka, MN 55343 USA
See Map
Phone: +1-952-540-4470
E-mail: info@respicardia.com
©2017 Respicardia®, Inc. CAUTION: Investigational Device. Limited by Federal (or United States) Law to investigational use.